Children's Allegra Hives is a drug owned by Chattem Inc Dba Sanofi Consumer Healthcare. It is protected by 19 US drug patents filed from 2013 to 2015. Out of these, 1 drug patents are active and 18 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 02, 2030. Details of Children's Allegra Hives's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US8933097 | Fexofenadine suspension formulation |
Aug, 2030
(5 years from now) | Active |
| US6723348 | Orodispersible tablets containing fexofenadine |
Nov, 2021
(2 years ago) |
Expired
|
|
US6037353 (Pediatric) | Method of providing an antihistaminic effect in a hepatically impaired patient |
Sep, 2017
(7 years ago) |
Expired
|
| US6037353 | Method of providing an antihistaminic effect in a hepatically impaired patient |
Mar, 2017
(7 years ago) |
Expired
|
|
US5932247 (Pediatric) | Pharmaceutical composition for piperidinoalkanol compounds |
Aug, 2015
(9 years ago) |
Expired
|
|
US5855912 (Pediatric) | Pharmaceutical compositions for piperidinalkanol compounds |
Aug, 2015
(9 years ago) |
Expired
|
|
US6113942 (Pediatric) | Pharmaceutical composition for piperidinoalkanol compounds |
Aug, 2015
(9 years ago) |
Expired
|
| US5738872 | Pharmaceutical composition for piperidinoalkanol compounds |
Feb, 2015
(9 years ago) |
Expired
|
| US5932247 | Pharmaceutical composition for piperidinoalkanol compounds |
Feb, 2015
(9 years ago) |
Expired
|
| US5855912 | Pharmaceutical compositions for piperidinalkanol compounds |
Feb, 2015
(9 years ago) |
Expired
|
| US6113942 | Pharmaceutical composition for piperidinoalkanol compounds |
Feb, 2015
(9 years ago) |
Expired
|
|
US7135571 (Pediatric) | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
Nov, 2014
(10 years ago) |
Expired
|
|
US7138524 (Pediatric) | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
Nov, 2014
(10 years ago) |
Expired
|
|
US5578610 (Pediatric) | Piperidine derivatives |
May, 2014
(10 years ago) |
Expired
|
| US7138524 | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
May, 2014
(10 years ago) |
Expired
|
| US7135571 | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
May, 2014
(10 years ago) |
Expired
|
| US5578610 | Piperidine derivatives |
Nov, 2013
(10 years ago) |
Expired
|
|
US6187791 (Pediatric) | Method of providing an antihistaminic effect in a hepatically impaired patient |
Nov, 2012
(12 years ago) |
Expired
|
|
US6399632 (Pediatric) | Method of providing an antihistaminic effect in a hepatically impaired patient |
Nov, 2012
(12 years ago) |
Expired
|
While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Children's Allegra Hives and ongoing litigations to help you estimate the early arrival of Children's Allegra Hives generic.
Children's Allegra Hives's Litigations
Children's Allegra Hives been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Nov 02, 1999, against patent number US6037353. The petitioner , challenged the validity of this patent, with YOUNG as the respondent. Click below to track the latest information on how companies are challenging Children's Allegra Hives's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US6037353 | November, 1999 |
Decision
(02 Nov, 1999) | YOUNG | |
US patents provide insights into the exclusivity only within the United States, but Children's Allegra Hives is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Children's Allegra Hives's family patents as well as insights into ongoing legal events on those patents.
Children's Allegra Hives's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Children's Allegra Hives's generic launch date based on the expiry of its last outstanding patent is estimated to be Aug 02, 2030 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Children's Allegra Hives Generics:
There are no approved generic versions for Children's Allegra Hives as of now.
How can I launch a generic of Children's Allegra Hives before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Children's Allegra Hives's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Children's Allegra Hives's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Children's Allegra Hives -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 30 mg/5 mL | 25 Jan, 2010 | 1 | 18 Nov, 2014 | 14 Mar, 2017 | Eligible |
| 30 mg, 60 mg and 180 mg |
About Children's Allegra Hives
Children'S Allegra Hives is a drug owned by Chattem Inc Dba Sanofi Consumer Healthcare. It is used for treating respiratory allergies, hives (urticaria), and their associated symptoms in adults and children. Children'S Allegra Hives uses Fexofenadine Hydrochloride as an active ingredient. Children'S Allegra Hives was launched by Chattem Sanofi in 2011.
Approval Date:
Children's Allegra Hives was approved by FDA for market use on 24 January, 2011.
Active Ingredient:
Children's Allegra Hives uses Fexofenadine Hydrochloride as the active ingredient. Check out other Drugs and Companies using Fexofenadine Hydrochloride ingredient
Treatment:
Children's Allegra Hives is used for treating respiratory allergies, hives (urticaria), and their associated symptoms in adults and children.
Dosage:
Children's Allegra Hives is available in the following dosage forms - tablet, orally disintegrating form for oral use, tablet form for oral use, suspension form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 30MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SUSPENSION | Discontinued | ORAL |
| 30MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET, ORALLY DISINTEGRATING | Discontinued | ORAL |
| 30MG | TABLET | Discontinued | ORAL |